Kaiser Aluminum Announces Quarterly Dividend Payment and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
102
Kaiser Aluminum Announces Quarterly Dividend Payment and $100 Million Increase in Share Repurchase Authorization

FOOTHILL RANCH, Calif., April 17, 2017 (GLOBE NEWSWIRE) -- Kaiser Aluminum Corporation (NASDAQ: KALU ) today announced that its Board of Directors has declared a quarterly cash dividend of $0.50 per share on the Company’s outstanding common stock. The dividend will be payable on May 15, 2017 to shareholders of record as of the close of business on April 27, 2017.

In addition, the Board of Directors authorized an additional $100 million for share repurchases. Including the amount available under the previous authorization, as of April 17, 2017 the total available for future share repurchases under the program was $149 million.

“We continue to see strong growth trends for our aerospace and automotive applications and improving demand for general engineering applications. The organic investments we have made to improve manufacturing efficiencies, expand capacity and enhance quality have further strengthened our competitive position and ability to drive earnings growth in the years ahead” said Jack A. Hockema, Chairman and CEO. “The 11% increase in our quarterly dividend announced earlier this year, along with the $100 million increase in our share repurchase authorization, underscores our confidence in the positive long-term outlook for our business,” stated Mr. Hockema.

Company Description

Kaiser Aluminum Corporation, headquartered in Foothill Ranch, Calif., is a leading producer of semi-fabricated specialty aluminum products, serving customers worldwide with highly-engineered solutions for aerospace and high-strength, general engineering, and custom automotive and industrial applications. The Company’s North American facilities produce value-added sheet, plate, extrusions, rod, bar, tube and wire products, adhering to traditions of quality, innovation and service that have been key components of its culture since the Company was founded in 1946. The Company’s stock is included in the Russell 2000® index and the S&P Small Cap 600® index.

Available Information For more information, please visit the Company’s web site at www.kaiseraluminum.com . The web site includes a section for investor relations under which the Company provides notifications of news or announcements regarding its financial performance, including Securities and Exchange Commission (SEC) filings, investor events, and earnings and other press releases. In addition, all Company filings submitted to the SEC are available through a link to the section of the SEC’s web site at www.sec.gov which includes: Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and Proxy Statements for the Company’s annual stockholders’ meetings and other information statements as filed with the SEC. In addition, the Company provides a webcast of its quarterly earnings calls and certain events in which management participates or hosts with members of the investment community.

This press release contains statements based on management’s current expectations, estimates and projections that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied. These factors include: (a ) the Company’s ability to achieve sales growth for aerospace, automotive and general engineering applications, (b) changes in economic or aluminum industry business conditions generally, including supply, demand and credit conditions and conditions in the markets served by the Company, including aerospace, defense, general engineering, automotive, distribution and other markets; (c) the ability of the Company to maintain sustainable performance improvement, identify and successfully execute organic investments and growth opportunities, including growth from the Company’s existing platform, and improve the Company’s manufacturing cost efficiencies, expand capacity and enhance quality further strengthening its competitive position and driving earnings growth; (d) the Company’s ability to successfully execute its strategy to maintain a low-cost position, provide high quality differentiated products and superior customer experience; (e) the impact of the Company's future earnings, cash flows, financial condition, capital requirements and other factors on its financial strength, flexibility, ability to pay or increase future dividends and repurchases and any decision by the Company's board of directors in that regard; and (f) other risk factors summarized in the Company’s reports filed with the Securities and Exchange Commission, including the Company's Form 10-K  for the year ended December 31, 2016. All information in this release is as of the date of the release. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.

Investor Relations and Public Relations Contact: Melinda C. Ellsworth Kaiser Aluminum Corporation (949) 614-1757

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

b1BANK Partners with Spiral to Enhance Community Banking Impact

Updated Category News Views 97

Enhanced Financial Wellness through Partnership NEW YORK--Today, Spiral, a personalized banking platform, announced a significant partnership with b1BANK, established as a community-focused banking institution. Through this collaboration, the two organizations aim to enhance financial wellness for customers, leveraging b1BANK's dedication to innovative banking solutions...

Continue Reading
AM Best Explores Trends Influencing For-Hire Trucking Industry

Updated Category News Views 168

Insights from AM Best's Latest Webinar on Trucking Trends Viewers can now delve into the highlights from the enlightening webinar hosted by AM Best, titled "For-Hire Trucking: The Risky Road Ahead." This event focused on the intricacies and challenges within the transportation-for-hire trucking sector, providing expert insights into risk management strategies and the...

Continue Reading
BitMart's Creative Campaign to Ignite Offline Crypto Engagement

Updated Category News Views 135

Introducing the Fox Hunt Delivery Campaign BitMart, a leading global cryptocurrency exchange, is excited to announce the launch of the Fox Hunt Delivery Campaign, a unique initiative aimed at boosting cryptocurrency adoption through engaging offline activities. This campaign offers an exciting chance for participants to earn USDT rewards simply by introducing new users to...

Continue Reading
Trinity Capital Inc. Fuels Alt Platform's Growth with $40M Credit

Updated Category News Views 273

Trinity Capital Inc. Supports Alt with Significant Credit Facility Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, is thrilled to announce a groundbreaking agreement with Alt, providing up to $40 million through an asset-based revolving credit facility. This funding aims to bolster Alt's innovative marketplace tailored for trading card...

Continue Reading
Everest Medicines Achieves Record Revenue and Growth in 2024

Updated Category News Views 506

Everest Medicines Achieves Remarkable Financial Success Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic...

Continue Reading